TP53 Mutations Are Associated with Increased Infections and Reduced Hematopoietic Cell Transplantation Rates in Myelodysplastic Syndrome and Acute Myeloid Leukemia

• Published in: Transplantation and cellular therapy Vol. 29; no. 6; pp. 390.e1 - 390.e10
• Main Authors: Marvin-Peek, Jennifer, Mason, Emily F., Kishtagari, Ashwin, Jayani, Reena V., Dholaria, Bhagirathbhai, Kim, Tae Kon, Engelhardt, Brian G., Chen, Heidi, Strickland, Stephen, Savani, Bipin, Ferrell, Brent, Kassim, Adetola, Savona, Michael, Mohan, Sanjay, Byrne, Michael
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2023
• Subjects: Acute myeloid leukemia; Myelodysplastic syndrome; TP53 mutation; TP53 mutation; Acute myeloid leukemia; Myelodysplastic syndrome
• ISSN: 2666-6367; 2666-6367
• DOI: 10.1016/j.jtct.2023.03.008

•Infections are more common in patients with TP53 mutations in myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML).•Infection is an independent risk factor for reduced transplantation rate.•Infections are associated worse overall survival in patients with TP53MUT MDS/AML. Although allogeneic hematopoietic cell transplantation (HCT) is the sole potentially curative therapy for patients with poor-risk myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML), only a minority of these patients undergo HCT. Patients with TP53-mutated (TP53MUT) MDS/AML are at particularly high risk, yet fewer TP53MUT patients undergo HCT compared with poor-risk TP53-wild type (TP53WT) patients. We hypothesized that TP53MUT MDS/AML patients have unique risk factors affecting the rate of HCT and thus investigated phenotypic changes that may prevent patients with TP53MUT MDS/AML from receiving HCT. In this single-center retrospective analysis of outcomes for adults with newly diagnosed MDS or AML (n = 352), HLA typing was used as a surrogate for physician “intent to transplant.” Multivariable logistic regression models were used to estimate odds ratios (ORs) for factors associated with HLA typing, HCT, and pretransplantation infections. Multivariable Cox proportional hazards models were used to create predicted survival curves for patients with and those without TP53 mutations. Overall, significantly fewer TP53MUT patients underwent HCT compared to TP53WT patients (19% versus 31%; P = .028). Development of infection was significantly associated with decreased odds of HCT (OR, .42; 95% CI, .19 to .90) and worse overall survival (hazard ratio, 1.46; 95% CI, 1.09 to 1.96) in multivariable analyses. TP53MUT disease was independently associated with increased odds of developing an infection (OR, 2.18; 95% CI, 1.21 to 3.93), bacterial pneumonia (OR, 1.83; 95% CI, 1.00 to 3.33), and invasive fungal infection (OR, 2.64; 95% CI, 1.34 to 5.22) prior to HCT. Infections were the cause of death in significantly more patients with TP53MUT disease (38% versus 19%; P = .005). With substantially more infections and decreased HCT rates in patients with TP53 mutations, this raises the possibility that phenotypic changes occurring in TP53MUT disease may affect infection susceptibility in this population and drastically impact clinical outcomes. [Display omitted]